Tvardi Therapeutics, Inc.
Income Statement
| Line Item | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|
| Revenue | $86.0K | $3.8M | $3.2M | $12.0M | $1.2M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $49.3M | $21.2M | $15.1M | $8.7M | $4.6M |
| SG&A Expense | $9.2M | $7.8M | $6.2M | $3.5M | $2.8M |
| Operating Income | $-58.4M | $-25.2M | $-18.1M | $-237.0K | $-6.2M |
| Operating Margin | -67,907.0% | -662.3% | -568.8% | -2.0% | -524.0% |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $-57.7M | $-25.1M | $-17.9M | $-4.0M | $-6.3M |
| Income Tax Expense | $-468.0K | $-397.0K | $-201.0K | $-30.0K | $-31.0K |
| Net Income | $-57.3M | $-24.7M | $-17.7M | $-4.0M | $-6.3M |
| Net Margin | -66,604.7% | -649.2% | -558.5% | -33.1% | -527.0% |
| EPS (Basic) | $-0.70 | $-0.33 | $-0.28 | $-0.05 | — |
| EPS (Diluted) | $-0.70 | $-0.33 | $-0.28 | $-0.05 | — |
| Shares Outstanding (Basic) | 81.8M | 73.9M | 62.9M | 62.0M | 49.5M |
| Shares Outstanding (Diluted) | 81.8M | 73.9M | 62.9M | 62.0M | 49.5M |
| Dividends Per Share | — | — | — | — | — |